evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,514 questions · 1,543 findings · 649 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 224 · 14.5%GRADE not reported 105 · 6.8%Very low 383 · 24.8%Low 447 · 29%Moderate 293 · 19%High 91 · 5.9%

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Statins vs placebo

Adverse events ‐ Muscle pain · patients with aortic valve stenosis

Statin showed no clear difference in adverse events ‐ Muscle pain compared with placebo (moderate certainty).

1 finding from 1 review

Fibrin‐based haemostatic agents vs placebo or no intervention

Serious adverse events Median · adults undergoing liver resection for cancer or benign disease

It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Grades 3 and 4 adverse events · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review